{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:00:44Z","timestamp":1783386044167,"version":"3.54.6"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070569"],"award-info":[{"award-number":["82070569"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03445-y","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:31:15Z","timestamp":1763983875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative efficacy of multiple drugs for non-alcoholic fatty liver disease: a Bayesian network meta-analysis"],"prefix":"10.1186","volume":"30","author":[{"given":"Zhile","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"3445_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356.","journal-title":"J Hepatol"},{"key":"3445_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3445_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3445_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"3445_CR5","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of non-alcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835.","journal-title":"Hepatology"},{"key":"3445_CR6","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388\u2013402.","journal-title":"J Hepatol"},{"key":"3445_CR7","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3445_CR8","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u201324.","journal-title":"Lancet"},{"key":"3445_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and non-alcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397.","journal-title":"Metabolism"},{"key":"3445_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793\u2013801.","journal-title":"J Hepatol"},{"key":"3445_CR11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691\u2013705.","journal-title":"Gut"},{"key":"3445_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3445_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S2468-1253(23)00275-3","volume":"9","author":"JA Thomas","year":"2024","unstructured":"Thomas JA, Kendall BJ, El-Serag HB, Thrift AP, Macdonald GA. Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2024;9:159\u201369.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3445_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337.","journal-title":"J Hepatol"},{"key":"3445_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19:60\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3445_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","volume":"67","author":"M Romero-G\u00f3mez","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67:829\u201346.","journal-title":"J Hepatol"},{"key":"3445_CR17","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/liv.12483","volume":"35","author":"KE Stewart","year":"2015","unstructured":"Stewart KE, Haller DL, Sargeant C, Levenson JL, Puri P, Sanyal AJ. Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver Int. 2015;35:936\u201343.","journal-title":"Liver Int"},{"key":"3445_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1756283X09105462","volume":"2","author":"WW Shields","year":"2009","unstructured":"Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and non-alcoholic steatohepatitis (NASH): a pilot trial. Ther Adv Gastroenterol. 2009;2:157\u201363.","journal-title":"Ther Adv Gastroenterol"},{"key":"3445_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2036.2004.01888.x","volume":"19","author":"A Uygun","year":"2004","unstructured":"Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19:537\u201344.","journal-title":"Aliment Pharmacol Ther"},{"key":"3445_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","volume":"65","author":"J Cui","year":"2016","unstructured":"Cui J, Philo L, Nguyen P, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2016;65:369\u201376.","journal-title":"J Hepatol"},{"key":"3445_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","volume":"23","author":"TR Joy","year":"2017","unstructured":"Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, et al. Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial. World J Gastroenterol. 2017;23:141.","journal-title":"World J Gastroenterol"},{"key":"3445_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3445_CR23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"3445_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"3445_CR25","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) (2023) Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). In: Cochrane. https:\/\/training.cochrane.org\/handbook. Accessed 31 Aug 2024."},{"key":"3445_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"3445_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"3445_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","volume":"7","author":"G van Valkenhoef","year":"2016","unstructured":"van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods. 2016;7:80\u201393.","journal-title":"Res Synth Methods"},{"key":"3445_CR29","doi-asserted-by":"crossref","unstructured":"Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, Kessels AG, Guyatt GH, GRADE Working Group. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630\u2013g5630","DOI":"10.1136\/bmj.g5630"},{"key":"3445_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","volume":"93","author":"R Brignardello-Petersen","year":"2018","unstructured":"Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36\u201344.","journal-title":"J Clin Epidemiol"},{"key":"3445_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jclinepi.2018.08.022","volume":"105","author":"R Brignardello-Petersen","year":"2019","unstructured":"Brignardello-Petersen R, Murad MH, Walter SD, McLeod S, Carrasco-Labra A, Rochwerg B, et al. GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks. J Clin Epidemiol. 2019;105:60\u20137.","journal-title":"J Clin Epidemiol"},{"key":"3445_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jclinepi.2018.11.025","volume":"108","author":"R Brignardello-Petersen","year":"2019","unstructured":"Brignardello-Petersen R, Mustafa RA, Siemieniuk RAC, Murad MH, Agoritsas T, Izcovich A, et al. Grade approach to rate the certainty from a network meta-analysis: addressing incoherence. J Clin Epidemiol. 2019;108:77\u201385.","journal-title":"J Clin Epidemiol"},{"key":"3445_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3900","volume":"371","author":"R Brignardello-Petersen","year":"2020","unstructured":"Brignardello-Petersen R, Florez ID, Izcovich A, Santesso N, Hazlewood G, Alhazanni W, et al. Grade approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ. 2020;371:m3900.","journal-title":"BMJ"},{"key":"3445_CR34","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","volume":"135","author":"GP Aithal","year":"2008","unstructured":"Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with non-alcoholic steatohepatitis. Gastroenterology. 2008;135:1176\u201384.","journal-title":"Gastroenterology"},{"key":"3445_CR35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/MEG.0000000000001369","volume":"31","author":"A Anushiravani","year":"2019","unstructured":"Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V. Treatment options for non-alcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. Eur J Gastroenterol Hepatol. 2019;31:613\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3445_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u201390.","journal-title":"Lancet"},{"key":"3445_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02948-4","author":"F Attaran","year":"2023","unstructured":"Attaran F, Emami S, Sohrabi M, Malek M, Ajdarkosh H, Khoonsari M, et al. Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and non-alcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial. BMC Gastroenterol. 2023. https:\/\/doi.org\/10.1186\/s12876-023-02948-4.","journal-title":"BMC Gastroenterol"},{"key":"3445_CR38","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med. 2006;355:2297\u2013307.","journal-title":"N Engl J Med"},{"key":"3445_CR39","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc19-0167","volume":"42","author":"F Bril","year":"2019","unstructured":"Bril F, Biernacki DM, Kalavalapalli S, et al. Role of vitamin E for non-alcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019;42:1481\u20138.","journal-title":"Diabetes Care"},{"key":"3445_CR40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","volume":"12","author":"H Chehrehgosha","year":"2021","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021;12:843\u201361.","journal-title":"Diabetes Ther"},{"key":"3445_CR41","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with non-alcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus. Ann Intern Med. 2016;165:305\u201315.","journal-title":"Ann Intern Med"},{"key":"3445_CR42","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3390\/ph15121516","volume":"15","author":"SH Elhini","year":"2022","unstructured":"Elhini SH, Wahsh EA, Elberry AA, El Ameen NF, Abdelfadil Saedii A, Refaie SM, et al. The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients. Pharmaceuticals. 2022;15:1516.","journal-title":"Pharmaceuticals"},{"key":"3445_CR43","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","volume":"61","author":"JW Eriksson","year":"2018","unstructured":"Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61:1923\u201334.","journal-title":"Diabetologia"},{"key":"3445_CR44","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","volume":"54","author":"A Flint","year":"2021","unstructured":"Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021;54:1150\u201361.","journal-title":"Aliment Pharmacol Ther"},{"key":"3445_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108487","volume":"170","author":"W Guo","year":"2020","unstructured":"Guo W, Tian W, Lin L, Xu X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and non-alcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. Diabetes Res Clin Pract. 2020;170:108487.","journal-title":"Diabetes Res Clin Pract"},{"key":"3445_CR46","doi-asserted-by":"publisher","first-page":"232","DOI":"10.30699\/jambs.30.140.232","volume":"30","author":"AA Hajiagha Mohammadi","year":"2022","unstructured":"Hajiagha Mohammadi AA, Khajeh Jahromi S, Ahmadi Gooraji S, Bastani A. Comparison of the therapeutic effects of melatonin, metformin and vitamin E on non-alcoholic fatty liver disease: a randomized clinical trial. J Adv Med Biomed Res. 2022;30:232\u201340.","journal-title":"J Adv Med Biomed Res"},{"key":"3445_CR47","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s12072-021-10242-2","volume":"15","author":"J-F Huang","year":"2021","unstructured":"Huang J-F, Dai C-Y, Huang C-F, et al. First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in non-alcoholic steatohepatitis patients. Hepatol Int. 2021;15:1136\u201347.","journal-title":"Hepatol Int"},{"key":"3445_CR48","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13410-021-00980-2","volume":"42","author":"M Hussain","year":"2022","unstructured":"Hussain M, Babar MZM, Tariq S, Ahmad MI, Akhtar L. Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients. Int J Diabetes Dev Ctries. 2022;42:290\u20136.","journal-title":"Int J Diabetes Dev Ctries"},{"key":"3445_CR49","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc17-0518","volume":"40","author":"D Ito","year":"2017","unstructured":"Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K, et al. Comparison of ipragliflozin and pioglitazone effects on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40:1364\u201372.","journal-title":"Diabetes Care"},{"key":"3445_CR50","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1111\/jdi.13279","volume":"11","author":"T Kinoshita","year":"2020","unstructured":"Kinoshita T, Shimoda M, Nakashima K, et al. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study. J Diabetes Investig. 2020;11:1612\u201322.","journal-title":"J Diabetes Investig"},{"key":"3445_CR51","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511\u201322.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3445_CR52","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in non-alcoholic steatohepatitis. N Engl J Med. 2021;384:1113\u201324.","journal-title":"N Engl J Med"},{"key":"3445_CR53","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1111\/jgh.15580","volume":"36","author":"S Phrueksotsai","year":"2021","unstructured":"Phrueksotsai S, Pinyopornpanish K, Euathrongchit J, Leerapun A, Phrommintikul A, Buranapin S, et al. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021;36:2952\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"3445_CR54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","volume":"135","author":"V Ratziu","year":"2008","unstructured":"Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for non-alcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) trial. Gastroenterology. 2008;135:100\u201310.","journal-title":"Gastroenterology"},{"key":"3445_CR55","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for non-alcoholic steatohepatitis. N Engl J Med. 2010;362:1675\u201385.","journal-title":"N Engl J Med"},{"key":"3445_CR56","first-page":"32","volume":"19","author":"K Shahebrahimi","year":"2017","unstructured":"Shahebrahimi K, Zulnoorian S, Almasi A, Sharifi A, Keshvarz A, Farshchian N. A comparison of the therapeutic effects of Metformin, Pioglitazone and Vitamin E in patients with non-alcoholic fatty liver. J Babol Univ Med Sci. 2017;19:32\u20138.","journal-title":"J Babol Univ Med Sci"},{"key":"3445_CR57","first-page":"106","volume":"21","author":"F Shidfar","year":"2016","unstructured":"Shidfar F, Ekhlasi G, Mohammadi R, Agah S, Zarrati M, Hosseini A, et al. Do symbiotic and vitamin E supplementation have favorite effects in non-alcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2016;21:106.","journal-title":"J Res Med Sci"},{"key":"3445_CR58","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","volume":"37","author":"H Taheri","year":"2020","unstructured":"Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Reza babaei M, et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2020;37:4697\u2013708.","journal-title":"Adv Ther"},{"key":"3445_CR59","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.clinre.2020.01.007","volume":"44","author":"L-Y Zhang","year":"2020","unstructured":"Zhang L-Y, Qu X-N, Sun Z-Y, Zhang Y. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2020;44:674\u201380.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3445_CR60","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002\u2013d4002.","journal-title":"BMJ"},{"key":"3445_CR61","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","volume":"160","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of non-alcoholic fatty liver disease: expert review. Gastroenterology. 2021;160:912\u20138.","journal-title":"Gastroenterology"},{"key":"3445_CR62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of non-alcoholic steatohepatitis. Gastroenterology. 2015;149:367-378.e5.","journal-title":"Gastroenterology"},{"key":"3445_CR63","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41574-020-0381-5","volume":"16","author":"F Magkos","year":"2020","unstructured":"Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16:545\u201355.","journal-title":"Nat Rev Endocrinol"},{"key":"3445_CR64","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, et al. Non-alcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e168\u2013e185.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3445_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4093\/dmj.2019.0208","volume":"44","author":"WH-H Sheu","year":"2020","unstructured":"Sheu WH-H, Chan SP, Matawaran BJ, et al. Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and abdominal obesity: an Asian perspective and expert recommendations. Diabetes Metab J. 2020;44:11.","journal-title":"Diabetes Metab J"},{"key":"3445_CR66","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","volume":"370","author":"RM Lago","year":"2007","unstructured":"Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129\u201336.","journal-title":"Lancet"},{"key":"3445_CR67","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1463-1326.2010.01225.x","volume":"12","author":"RE Aubert","year":"2010","unstructured":"Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab. 2010;12:716\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"3445_CR68","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125\u201335.","journal-title":"Lancet"},{"key":"3445_CR69","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/dmrr.666","volume":"22","author":"RK Schindhelm","year":"2006","unstructured":"Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006;22:437\u201343.","journal-title":"Diabetes Metab Res Rev"},{"key":"3445_CR70","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.1111\/hepr.12456","volume":"45","author":"Y Seko","year":"2015","unstructured":"Seko Y, Sumida Y, Tanaka S, et al. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res. 2015;45:E53-61.","journal-title":"Hepatol Res"},{"key":"3445_CR71","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner DE, Brunt EM, Wilson LA, et al. Association of histologic disease activity with progression of non-alcoholic fatty liver disease. JAMA Netw Open. 2019;2:e1912565.","journal-title":"JAMA Netw Open"},{"key":"3445_CR72","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32\u201342.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3445_CR73","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","volume":"10","author":"N Stefan","year":"2022","unstructured":"Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10:284\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3445_CR74","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1124\/dmd.110.035006","volume":"38","author":"RN Hardwick","year":"2010","unstructured":"Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. Diversity in antioxidant response enzymes in progressive stages of human non-alcoholic fatty liver disease. Drug Metab Dispos. 2010;38:2293\u2013301.","journal-title":"Drug Metab Dispos"},{"key":"3445_CR75","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/hep.30368","volume":"71","author":"E Vilar-Gomez","year":"2020","unstructured":"Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with non-alcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71:495\u2013509.","journal-title":"Hepatology"},{"key":"3445_CR76","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/0003-4819-142-1-200501040-00110","volume":"142","author":"ER Miller","year":"2005","unstructured":"Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37.","journal-title":"Ann Intern Med"},{"key":"3445_CR77","doi-asserted-by":"publisher","first-page":"c5702","DOI":"10.1136\/bmj.c5702","volume":"341","author":"M Schurks","year":"2010","unstructured":"Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341:c5702\u2013c5702.","journal-title":"BMJ"},{"key":"3445_CR78","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/jama.2011.1437","volume":"306","author":"EA Klein","year":"2011","unstructured":"Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer. JAMA. 2011;306:1549.","journal-title":"JAMA"},{"key":"3445_CR79","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/S0140-6736(03)13637-9","volume":"361","author":"DP Vivekananthan","year":"2003","unstructured":"Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361:2017\u201323.","journal-title":"Lancet"},{"key":"3445_CR80","first-page":"CD015033","volume":"2024","author":"H Wen","year":"2024","unstructured":"Wen H, Deng H, Yang L, Li L, Lin J, Zheng P, et al. Vitamin E for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2024;2024:CD015033.","journal-title":"Cochrane Database Syst Rev"},{"key":"3445_CR81","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","volume":"18","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol. 2022;18:55\u201366.","journal-title":"Nat Rev Endocrinol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03445-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03445-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03445-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:14:41Z","timestamp":1764180881000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03445-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3445"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03445-y","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1164"}}